Showing 1 to 12 of 12 results
White House Links Paracetamol Use in Pregnancy to Autism; EMA Disputes Claim
The White House announced a link between paracetamol use during pregnancy and childhood autism, a claim disputed by the European Medicines Agency (EMA), which cites a lack of conclusive evidence from reviewed studies.
White House Links Paracetamol Use in Pregnancy to Autism; EMA Disputes Claim
The White House announced a link between paracetamol use during pregnancy and childhood autism, a claim disputed by the European Medicines Agency (EMA), which cites a lack of conclusive evidence from reviewed studies.
Progress
40% Bias Score
EMA Reverses Alzheimer's Drug Block, Approves Donanemab Under Strict Protocols
The European Medicines Agency (EMA) reversed its decision to block Donanemab, a new Alzheimer's treatment, approving it for early-stage patients with at most one copy of a specific gene under strict safety protocols after initially deeming the risks outweighed the benefits; Donanemab slows Alzheimer...
EMA Reverses Alzheimer's Drug Block, Approves Donanemab Under Strict Protocols
The European Medicines Agency (EMA) reversed its decision to block Donanemab, a new Alzheimer's treatment, approving it for early-stage patients with at most one copy of a specific gene under strict safety protocols after initially deeming the risks outweighed the benefits; Donanemab slows Alzheimer...
Progress
40% Bias Score
EU Approves Twice-Yearly HIV Prevention Injection
European regulators approved Gilead's lenacapavir, a twice-yearly HIV prevention injection, 100% effective in trials, offering a significant advancement amid rising HIV cases (24,700 new diagnoses in 2023, up 11.8% from 2022).
EU Approves Twice-Yearly HIV Prevention Injection
European regulators approved Gilead's lenacapavir, a twice-yearly HIV prevention injection, 100% effective in trials, offering a significant advancement amid rising HIV cases (24,700 new diagnoses in 2023, up 11.8% from 2022).
Progress
40% Bias Score
EMA Restricts Azithromycin Use to Combat Antimicrobial Resistance
After a year-and-a-half review, the EMA recommends restricting azithromycin use in the EU for several indications due to rising antimicrobial resistance, impacting treatment for infections like acne, Helicobacter pylori, and asthma, with varying implementations across member states.
EMA Restricts Azithromycin Use to Combat Antimicrobial Resistance
After a year-and-a-half review, the EMA recommends restricting azithromycin use in the EU for several indications due to rising antimicrobial resistance, impacting treatment for infections like acne, Helicobacter pylori, and asthma, with varying implementations across member states.
Progress
20% Bias Score
EMA Rejects Alzheimer's Drug Donanemab Due to Safety Concerns
The European Medicines Agency (EMA) rejected Eli Lilly's Alzheimer's drug, donanemab, due to concerns about deadly side effects, impacting 7 million Europeans with Alzheimer's despite its 35% efficacy in slowing dementia progression in trials; the decision contrasts with the eventual approval of a s...
EMA Rejects Alzheimer's Drug Donanemab Due to Safety Concerns
The European Medicines Agency (EMA) rejected Eli Lilly's Alzheimer's drug, donanemab, due to concerns about deadly side effects, impacting 7 million Europeans with Alzheimer's despite its 35% efficacy in slowing dementia progression in trials; the decision contrasts with the eventual approval of a s...
Progress
40% Bias Score
EMA Recommends Approval of Alzheimer's Drug Lecanemab
The European Medicines Agency (EMA) again recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients after previously rejecting it due to safety concerns; a new analysis shows benefits outweigh risks in a specific patient subgroup; the drug is already approved in the USA.
EMA Recommends Approval of Alzheimer's Drug Lecanemab
The European Medicines Agency (EMA) again recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients after previously rejecting it due to safety concerns; a new analysis shows benefits outweigh risks in a specific patient subgroup; the drug is already approved in the USA.
Progress
40% Bias Score
EU Drug Shortages Reach Record Levels, Highlighting Systemic Issues
A European Court of Auditors report reveals record-high drug shortages in the EU in 2023 and 2024, caused by a lack of a common framework for managing shortages and fragmented data across member states, impacting patient care and highlighting the EU's strategic vulnerability in drug supply.
EU Drug Shortages Reach Record Levels, Highlighting Systemic Issues
A European Court of Auditors report reveals record-high drug shortages in the EU in 2023 and 2024, caused by a lack of a common framework for managing shortages and fragmented data across member states, impacting patient care and highlighting the EU's strategic vulnerability in drug supply.
Progress
16% Bias Score
EMA Conditionally Approves Alzheimer's Drug Donanemab Under Strict Monitoring
The European Medicines Agency conditionally approved Eli Lilly's Donanemab for early-stage Alzheimer's patients with one or zero copies of a specific gene, reversing its initial rejection due to the risk of fatal brain swelling and bleeding, mirroring a similar approval process for Lecanemab.
EMA Conditionally Approves Alzheimer's Drug Donanemab Under Strict Monitoring
The European Medicines Agency conditionally approved Eli Lilly's Donanemab for early-stage Alzheimer's patients with one or zero copies of a specific gene, reversing its initial rejection due to the risk of fatal brain swelling and bleeding, mirroring a similar approval process for Lecanemab.
Progress
40% Bias Score
EMA Conditionally Approves Alzheimer's Drug Donanemab Under Strict Safety Protocols
The European Medicines Agency (EMA) conditionally approved the Alzheimer's drug donanemab (Kisunla) for patients with one or zero copies of a gene linked to increased risk, after initially rejecting it due to the risk of brain swelling and bleeding; the drug will be available only under strict safet...
EMA Conditionally Approves Alzheimer's Drug Donanemab Under Strict Safety Protocols
The European Medicines Agency (EMA) conditionally approved the Alzheimer's drug donanemab (Kisunla) for patients with one or zero copies of a gene linked to increased risk, after initially rejecting it due to the risk of brain swelling and bleeding; the drug will be available only under strict safet...
Progress
32% Bias Score
EMA Blocks Alzheimer's Drug Donanemab Due to Fatal Side Effects
The European Medicines Agency (EMA) blocked Lilly's Alzheimer's drug, donanemab (Kisunla), due to potentially fatal side effects, despite its approval in the US and UK; the drug slowed Alzheimer's progression by 35% in trials but caused three deaths, two linked to a gene increasing Alzheimer's risk;...
EMA Blocks Alzheimer's Drug Donanemab Due to Fatal Side Effects
The European Medicines Agency (EMA) blocked Lilly's Alzheimer's drug, donanemab (Kisunla), due to potentially fatal side effects, despite its approval in the US and UK; the drug slowed Alzheimer's progression by 35% in trials but caused three deaths, two linked to a gene increasing Alzheimer's risk;...
Progress
52% Bias Score
False Claim: EMA Admitted mRNA Vaccines Lack Official Approval
Uncut-News falsely claims the EMA admitted mRNA vaccines are unapproved, citing a document about veterinary vaccines; however, the EMA's position emphasizes the rigorous testing and approval of human mRNA vaccines used in the COVID-19 pandemic.
False Claim: EMA Admitted mRNA Vaccines Lack Official Approval
Uncut-News falsely claims the EMA admitted mRNA vaccines are unapproved, citing a document about veterinary vaccines; however, the EMA's position emphasizes the rigorous testing and approval of human mRNA vaccines used in the COVID-19 pandemic.
Progress
68% Bias Score
EMA Recommends Approval of Alzheimer's Drug Lecanemab
The European Medicines Agency (EMA) recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients with mild cognitive impairment or mild dementia after a previous rejection due to safety concerns; the drug only slightly slows disease progression and is suitable for a small patient su...
EMA Recommends Approval of Alzheimer's Drug Lecanemab
The European Medicines Agency (EMA) recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients with mild cognitive impairment or mild dementia after a previous rejection due to safety concerns; the drug only slightly slows disease progression and is suitable for a small patient su...
Progress
48% Bias Score
Showing 1 to 12 of 12 results